Genes involved in the induction and resolution of eczema using the Atopy Patch Test as an in vivo model for atopic dermatitis

Genes involved in the induction and resolution of eczema using the Atopy Patch Test as an in vivo model for atopic dermatitis - APT and markers for eczema

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44326

Enrollment

Registered

2014-04-10

Start date

2014-12-16

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis (AD) atopic eczema (AE)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: age 18-70 years AE positive APT

Exclusion criteria

Exclusion criteria: Active AE on the patients back - Not sensitized to aeroallergens, such as house dust mite (demonstrated by a positive immuno CAP test for these allergens) - Treatment with systemic immunosuppressive medication (including corticosteroids and cyclosporin) within the 4 weeks prior to having the biopsies performed. In addition, weekly use of equal or more than 50 grams of topical corticosteroids class IV or weekly use of equal or more than 100 grams of topical corticosteroids class III. - Exposure of biopsy location to high levels of UV radiation (e.g. UV-therapy, use of tanning booths, sunbathing) in the 2 weeks prior to taking biopsies - Use of antihistamines in the week or days before and during the APT ( see patientinformation 'Bijlage 4: medicatielijst')

Design outcomes

Primary

Measure	Time frame
Ex vivo: mRNA expression levels of the measured markers with qPCR in snap frozen tissue.	—

Secondary

Measure	Time frame
Ex vivo: localization of the markers with IHC on frozen slides.	—

Countries

Netherlands

Outcome results